gefitinib has been researched along with pterostilbene in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (pterostilbene) | Trials (pterostilbene) | Recent Studies (post-2010) (pterostilbene) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 549 | 8 | 480 |
| Protein | Taxonomy | gefitinib (IC50) | pterostilbene (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 10 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.82 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.5867 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 10 | |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.82 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 5.1 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.7 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.82 | |
| Transient receptor potential cation channel subfamily A member 1 | Rattus norvegicus (Norway rat) | 7.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B | 1 |
| Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B | 1 |
| Hu, C; Liu, B; Liu, P; Lu, M; Wu, F; Xiong, H | 1 |
3 other study(ies) available for gefitinib and pterostilbene
| Article | Year |
|---|---|
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Drug Interactions; Gefitinib; Glioblastoma; Humans; Quinazolines; Sertraline; Stilbenes | 2013 |
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome | 2016 |
Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Heterografts; Humans; MAP Kinase Kinase 1; MicroRNAs; Oncogene Protein v-akt; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stilbenes | 2019 |